# A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine

> **NCT03962738** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 846 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Lasmiditan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03962738
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-31
- **Primary completion:** 2020-06-08
- **Final completion:** 2020-06-08
- **Target enrollment:** 846 (ACTUAL)
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03962738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03962738, "A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03962738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*